Care Transitions App for Patients With Multiple Chronic Conditions

Sponsor
Brigham and Women's Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06051058
Collaborator
Agency for Healthcare Research and Quality (AHRQ) (U.S. Fed)
798
2
18

Study Details

Study Description

Brief Summary

The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Care Transitions App
N/A

Detailed Description

Care transitions are a vulnerable period for patients, leading to a 20% rate of readmissions, 11% rate of post-discharge adverse drug events, 15% rate of falls, and 29% rate of total post-discharge adverse events. Hospital discharge for patients with multiple chronic conditions (MCC) is a challenge for the hospital care teams, primary care providers (PCPs) and patients/caregivers who face the challenge of complex medication regimens, as well as patient-specific challenges in fall prevention strategies. Specific challenges include poor communication among inpatient providers, patients, and ambulatory providers, poor quality and timeliness of discharge documentation, suboptimal patient understanding of post-discharge plans of care and their ability to carry out these plans, medication discrepancies and non-adherence after discharge, failure to follow up the results of tests pending at time of discharge, failure to schedule necessary ambulatory appointments, tests, and procedures, and lack of timely follow-up with ambulatory providers.

These risks are especially important for people living with multiple chronic conditions (PLWMCC), such as diabetes (DM), congestive heart failure (CHF), and chronic kidney disease (CKD). Each of these conditions requires a complex medication regimen which is often altered during the hospital admission. Often, the medications cannot be changed back to their original dose at the time of discharge because patients are eating less than usual, have become dehydrated, and their kidney function has been affected by nephrotoxic medications. Clearance of medications such as insulin is also altered and limited physical activity in the hospital places patients at increased risk for falls after discharge. All of these factors increase the risk of adverse events in the post-discharge period. An overarching goal of the intervention is to overcome common care transition challenges by simplifying the information patients and caregivers receive and empowering them to carry out their care plans.

Previous research supports the use of mobile apps for improving health outcomes among those living with chronic illness. While many apps are available for chronic disease management, most of them focus on a single chronic illness such as diabetes or heart failure, or self-management area such as medication management, sleep, or pain and do not specifically target the period of transition from hospital to home. The intervention will fill an existing gap by developing, rigorously testing, and disseminating a comprehensive Care Transitions App for patients with MCC that will provide comprehensive care transition information for disease self-management, medication safety, and fall prevention in a format that is simple and actionable.

The investigators will conduct a pragmatic randomized controlled trial in an academic medical center (Brigham and Women's Hospital) and primary care clinics to test the effectiveness of the Care Transitions App enrolling patients age 55 or older with MCC including Diabetes, congestive heart failure, and/or chronic kidney disease.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
798 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The design is a randomized trial with patients recruited inpatient from Brigham and Women's Hospital and nested within primary care practices in the MGB healthcare system. The unit of randomization is the patient.The design is a randomized trial with patients recruited inpatient from Brigham and Women's Hospital and nested within primary care practices in the MGB healthcare system. The unit of randomization is the patient.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Care Transitions App for Patients With Multiple Chronic Conditions
Anticipated Study Start Date :
Aug 1, 2024
Anticipated Primary Completion Date :
Feb 1, 2026
Anticipated Study Completion Date :
Feb 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental: Care Transitions App

Use of the Care Transitions App to support the care transition for patients hospitalized and discharged with multiple chronic conditions will be compared to usual care.

Behavioral: Care Transitions App
Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.

No Intervention: No Intervention: Usual Care

Usual care transition care for patients hospitalized and discharged with multiple chronic conditions.

Outcome Measures

Primary Outcome Measures

  1. To determine the effect of the Care Transitions App on post-discharge adverse events [30 Days]

    Overall rate of post-discharge adverse events

Secondary Outcome Measures

  1. To determine the effect of the Care Transitions App on the 30-day readmission rate [30 Days]

    30-day readmission rate

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult patients (55+) with a Brigham PCP or appointment in one of the 15 locations discharging from a BWH general medicine unit

  • Discharging to home, home health care service or assisted living

  • Fluent in spoken English in patient or healthcare proxy

  • Patients with at least one of the conditions listed below + one additional chronic condition on the problem list.

  • Patient with heart failure on the problem list

  • Patient with type 2 diabetes on the problem list

  • Patient with chronic kidney disease on the problem list

Exclusion Criteria:
  • Adult patients (55+) with Westwood, Pembroke, or Transition Clinic PCP admitted to ICU, OBGYN, Surgical, Cardiology, Oncology, Orthopedics, or other Specialty Unit

  • Pregnant

  • Prisoner, institutionalized individual or in police custody

  • Discharge planned within 3 hours of screening

  • Patient too ill to participate or with active psychosis/serious mental illness, delirium, or severe dementia

  • Not fluent in spoken English in patient and health proxy

  • Unlikely to be discharged to home

  • Lacks a device capable of accessing the app

  • Lack of a working telephone for 30-day follow-up

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Brigham and Women's Hospital
  • Agency for Healthcare Research and Quality (AHRQ)

Investigators

  • Principal Investigator: Lipika Samal, MD, MPH, Brigham and Women's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lipika Samal, Principal Investigator, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT06051058
Other Study ID Numbers:
  • 2023P001447
First Posted:
Sep 22, 2023
Last Update Posted:
Sep 28, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 28, 2023